Pfizer Still Bullish On China
With portfolios well-matched to market needs, there are no expectations of a slowdown in the near future for Pfizer in China. The company will continue to be “opportunistic” in making investments to drive its business there.
You may also be interested in...
May has brought a flurry of new pharma executive moves in Japan and China.
After a long seven-year hiatus, China is finally moving to update its national reimbursement drug list, but the process will involve huge numbers of experts and the benefits of inclusion may not be as immediate or as extensive as appear at first sight.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.